Omeros (OMER) Assets Average (2011 - 2026)
Omeros (OMER) posted Assets Average of $305.9 million for Q1 2026, up 19.65% sequentially from $255.7 million in Q4 2025, and up 19.44% YoY from $256.1 million in Q1 2025.
Omeros (OMER) Assets Average (2011 - 2026) Analysis & Trends
Omeros has reported Assets Average for 16 years, with the latest figure at $305.9 million in Q1 2026.
- Quarterly Assets Average rose 19.44% year-over-year to $305.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $305.9 million (up 19.44% YoY) and the FY2025 annual result came in at $301.4 million, down 8.03% from the prior year.
- Assets Average rose to $305.9 million in Q1 2026 per OMER's latest filing, from $255.7 million in the prior quarter.
- Over five years, Assets Average peaked at $575.6 million in Q1 2023 and troughed at $193.1 million in Q3 2025.
- A 5-year average of $376.8 million and a median of $394.3 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average soared 198.78% in 2022, then sank 45.11% in 2025.
- Over 5 years, Assets Average stood at $524.3 million in 2022, then decreased by 16.9% to $435.7 million in 2023, then slumped by 32.24% to $295.2 million in 2024, then declined by 13.39% to $255.7 million in 2025, then rose by 19.65% to $305.9 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $305.9 million, $255.7 million, and $193.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 286.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 286.50 Mn |
| Mar 31, 2026 | 305.90 Mn |
| Dec 31, 2025 | 255.67 Mn |
| Sep 30, 2025 | 193.14 Mn |
| Jun 30, 2025 | 217.87 Mn |
| Mar 31, 2025 | 256.12 Mn |
| Dec 31, 2024 | 295.21 Mn |
| Sep 30, 2024 | 334.82 Mn |
| Jun 30, 2024 | 396.90 Mn |
| Mar 31, 2024 | 407.88 Mn |
| Dec 31, 2023 | 435.67 Mn |
| Sep 30, 2023 | 510.25 Mn |
| Jun 30, 2023 | 543.78 Mn |
| Mar 31, 2023 | 575.55 Mn |
| Dec 31, 2022 | 524.26 Mn |
| Sep 30, 2022 | 401.59 Mn |
| Jun 30, 2022 | 357.45 Mn |
| Mar 31, 2022 | 394.27 Mn |
| Dec 31, 2021 | 271.35 Mn |
| Sep 30, 2021 | 134.41 Mn |